An efficacy analysis of anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to multifocal choroiditis and comparison with wet age-related macular degeneration.

CONCLUSIONS: IVT ranibizumab resulted in good clinical outcomes for juxtafoveal CNV secondary to MFC and wet AMD, but the average number of injections used in MFC was fewer than that used in wet AMD over a 6-month observation period. Compared with the wet AMD group, visual acuity was obviously improved in the MFC group at 6 months.
PMID: 29616508 [PubMed - in process]

Source: J Zhejiang Univ Sci ... - April 1, 2018 Category: Science Authors: Feng L, Hu JH, Chen J, Xie X Tags: J Zhejiang Univ Sci B Source Type: research